Drug Profile
Research programme: anti-infectives - Ranbaxy/Merck
Latest Information Update: 24 Aug 2011
Price :
$50
*
At a glance
- Originator Ranbaxy Laboratories
- Developer Merck & Co; Ranbaxy Laboratories
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 05 Jan 2011 Discontinued for Infections in India (unspecified route)
- 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo Company
- 12 May 2008 Research in Infections in India(unspecified route)